The Medical World Thinks You Are Too Old to Matter

I am currently staring at a glass of Malbec that costs more than my first car. (That car was a 1994 Geo Metro with a door that only opened from the outside, so the bar is remarkably low.) My knees made a sound like a bag of potato chips being crushed when I sat down. I am officially older. And yet, if I were to receive a serious diagnosis tomorrow, the medical establishment might just pretend I do not exist for the sake of a clean spreadsheet. I am currently staring at a glass of deep red wine and questioning if I would even qualify for a clinical study on hangovers. (My knees make a sound like a wet paper bag being torn every time I attempt to stand, so I assume I am already a medical outlier.) It is highly probable that I would not. It is a spectacular kind of arrogance. It is a mess.

We are currently drafting the blueprints for the future of oncology by staring exclusively at data from the youngest, most pristine subset of the human race. (I remember being twenty-five, but I do not remember being that productive.) Then, we apply those findings to elderly women whose biology is fundamentally different. It is precisely like testing a high performance sports car on a perfectly smooth track in the Mediterranean and then expressing genuine confusion when that same engine fails to turn over on a gravel road in the middle of a blizzard. Science is ignoring the slush. I once attempted to navigate a convertible through a blinding Vermont snowstorm because I possessed the unique combination of youth and staggering arrogance. (That is exactly the flavor of hubris the pharmaceutical industry is serving up to us right now.) I have spent two decades documenting the messy intersection of personal finance and healthcare. I have witnessed some truly historic failures, but this quiet, systematic erasure of the elderly feels especially cold. This is not merely a clerical error or a lack of recruitment effort. It is a sanitized version of science that ignores the messy reality of human aging.

The Math of Exclusion

Let us look at the actual numbers. The American Cancer Society reports that the median age for a breast cancer diagnosis is sixty-two. (I am approaching that number with the speed of a runaway freight train.) For ovarian cancer, it is sixty-three. You would think the clinical trials would be full of women who have seen a few decades. You would be wrong. They are not there. If you are sixty-five and you have a touch of arthritis or you take a pill for your cholesterol, you are suddenly a liability to the data set. You are too complicated. You are too real. (I have a theory that researchers would prefer to test medicine on ghosts, as they have very few pre-existing conditions and never complain about the hospital food.)

My friend Sarah is a brilliant oncologist who once accidentally tipped a waiter with a prescription pad. (He did not appreciate the humor, though the dosage was quite generous.) She told me that researchers want pure data. They want participants with no other health issues. But elderly women are messy. They have lived. Apparently, living long enough to have a medical history makes you a bad data point. He meant that it is harder to tell if a side effect is caused by the drug or by the patient's age. (I suggested that perhaps the noise is actually the sound of reality, but he just blinked at me and checked his watch.) A 2024 study in the Journal of Medicine found that age-related factors are often used as excuses to keep the elderly out of the room. It is a sanitized version of science. It ignores reality. It is a high-stakes gamble where the house always wins and the patient loses her dignity and her health.

The Noise Problem

My neighbor Bob - who is seventy-four and spends most of his time yelling at squirrels - is a perfect example of why this matters. (The squirrel usually wins, mostly because it has better reflexes and does not have a mortgage.) Bob has a pacemaker. If Bob were a woman with a cancer diagnosis, he would likely be excluded from a trial because he has a pacemaker. Why? Because the pacemaker makes the data noisy. That is the term they use. Noisy. As if Bob is a radio station with bad reception instead of a human being. It is a high-stakes gamble where the house always wins and the patient loses her dignity.

The risk of taking a drug that was never tested on your age group is significant. It is a gamble I would not take. (And I once bet my entire security deposit on a horse named Sad Breakfast, so I know a bad gamble.) We are treating the elderly with guesswork. We are using a map of Florida to navigate the streets of London. It does not work. It cannot work. We need to stop pretending that seventy is the same as thirty. It is time to let the noise in. The noise is where the truth lives. (I tried telling the squirrel this, but it just threw an acorn at my head.)

The Logistics of Erasure

There is also the matter of simple logistics, which is where the medical system truly shows its lack of imagination. For a woman in her seventies living in a rural area, traveling three hours each way for a blood draw is not just an inconvenience. (I can barely handle a twenty minute drive to the grocery store without needing a nap and a celebratory snack.) It is an impossibility. By moving some of these requirements to local clinics or even using home health visits, we can diversify the participant pool. It is about removing the friction that keeps the elderly on the sidelines. I once missed a very important job interview because the office was on the fourth floor and the elevator was broken. (I was in my twenties then, so I have no excuse other than a total lack of cardiovascular endurance and a deep-seated resentment of stairs.)

We are also seeing a push for "age-inclusive" trial design that specifically mandates a certain percentage of older participants. This is a crucial step. Without a mandate, researchers will always take the path of least resistance. They will always pick the healthy thirty-year-old because it makes their job easier. (It is the medical equivalent of only hiring interns who do not require health insurance or a living wage.) These trials prioritize the inclusion of elderly patients by making the requirements more flexible. They allow for the presence of other health conditions, acknowledging that an eighty-year-old woman is allowed to have more than one thing wrong with her at a time. It is supposed to be true. And the truth is that cancer is a disease of aging. (I am getting a bit worked up here, but after twenty years of watching pharmaceutical companies prioritize their stock price over geriatric safety, I think I have earned a little outrage.)

How to Navigate the System for Yourself or a Loved One

If you or someone you love is facing a cancer diagnosis at an advanced age, you cannot afford to be passive. You must be the loudest person in the room. (I am excellent at being the loudest person in the room, especially when the restaurant runs out of the good bread.) It is also important to seek out a geriatric oncologist if possible. These are specialists who understand the delicate balance between treating the cancer and preserving the patient's quality of life. They are much more likely to be aware of age-inclusive trials and to understand how to adjust dosages for older bodies. You should also look into patient advocacy groups that specialize in elderly care. These organizations have the resources to help you navigate the complex bureaucracy of the medical system. They can help you find trials, understand the risks, and even provide support for transportation and logistics. Do not try to do this alone.

I once tried to find my way out of a suburban shopping mall without a map and nearly became a permanent resident of the food court. (The mall was particularly traumatizing; I am still not sure if I ever truly escaped the scent of cinnamon rolls.) Use the expertise of those who have been there before. Advocacy is not just a buzzword. It is a survival strategy. Finally, remember that you have the right to ask about the data behind the treatment being offered. If a doctor recommends a specific chemotherapy regimen, ask them how many women over seventy were in the study that approved it. If the answer is "none" or "we do not know," you have every right to be skeptical. It is your body. You are not a data point to be sanitized for the sake of a clean laboratory report. You are a human being who has survived decades of existence, and you deserve a medical system that respects that history.

The Bottom Line

The systematic exclusion of elderly women from cancer trials is a quiet crisis that has been simmering in the background of oncology for decades. It is a product of a research culture that prizes ease and simplicity over the complex, aging reality of the human population. We cannot continue to treat the most vulnerable patients with medicine that was never tested on people like them. It is medically irresponsible, and it is socially indefensible. (I am not a doctor, but I have been around long enough to know when a system is broken, and this one is held together by little more than hope and old paperwork.)

The path forward requires a fundamental shift in how we value older lives. We need to demand that clinical trials reflect the demographics of the disease they are trying to cure. This means broader inclusion criteria, decentralized trial locations, and a commitment to understanding the unique biology of aging. It is time to bring the invisible patient into the light. We owe it to our mothers, our grandmothers, and eventually, to ourselves. (Because unless someone discovers a fountain of youth in the next twenty minutes, we are all heading toward that "elderly" demographic, and I for one would like to know the medicine I am taking actually works on a person with a few wrinkles and a long history of questionable decisions.) We have to stop treating the elderly as the "other" in medical research. They are the majority. It is time we started treating them like it. (I am finishing my wine now, and I am more convinced than ever that the lab coats need to step out of their sterile rooms and spend a day in a real clinic. It might be loud, and it might be messy, but it is the only way to find the truth.)

⏱️ Quick Takeaways

Frequently Asked Questions

❓ Why are older women specifically excluded from ovarian cancer trials?

The short answer involves the quest for "perfect" data. Researchers often fear that older women, who may have other health issues like diabetes or heart disease, will muddy the results of the trial. If a patient dies or has a complication, the researchers want to be sure it was the cancer or the drug, not a pre-existing condition. This leads to overly strict exclusion criteria that keep the elderly out of the study entirely. It is a practice that prioritizes the pharmaceutical company's success over the patient's actual needs. (It is essentially medical gatekeeping, and I find it utterly exhausting.)

❓ Are there risks to joining a clinical trial as an older adult?

The reality is that there are risks for any patient in a trial, but they can be more pronounced for the elderly. Because older bodies often process drugs more slowly, the risk of toxicity can be higher. However, the risk of taking a drug that was never tested on your age group at all is also significant. A trial at least provides a high level of monitoring and specialized care that you might not receive with standard treatment. It is a balance that you should discuss thoroughly with a geriatric oncologist. (I would also suggest bringing a notebook and a very cynical friend to these appointments.)

❓ How can I find a trial that accepts patients over 70?

This depends on your specific diagnosis, but the best place to start is the National Cancer Institute's database. You should specifically look for trials that mention "pragmatic design" or "geriatric assessment." You can also use advocacy organizations that focus on older adults. Do not be afraid to contact the trial coordinators directly and ask about their age demographics. If they seem hesitant or dismissive, that is a sign that the trial might not be the right fit for your needs. (If they treat you like a burden before you even sign up, imagine how they will treat you after they have your data.)

❓ What is a geriatric assessment and why does it matter?

Think of a geriatric assessment as a deep dive into how you are actually functioning in your daily life. It looks at your physical strength, your cognitive health, your nutrition, and your social support. It is much more accurate than just looking at your age. In a clinical trial, this assessment helps doctors understand if a patient is "fit" or "frail," which is a much better predictor of how they will handle treatment than their birth year. If a trial uses these assessments, it is a sign they are taking age seriously. (It is the difference between judging a book by its cover and actually reading the first three chapters.)

❓ Will my insurance cover the costs of a clinical trial?

Here is the thing about insurance: it is complicated. Most major insurers are required to cover the routine costs of care for patients in clinical trials, but they might not cover the "research" costs. Usually, the company running the trial covers the cost of the drug being tested and any extra tests required by the study. You must have a very clear conversation with both the trial coordinator and your insurance provider before you sign anything. Do not assume anything is covered until you see it in writing. (Insurance companies love fine print more than I love a quiet Tuesday afternoon.)

References

Disclaimer: This article is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or clinical trial participation. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.